Category: Publications
Search News
Switching on survival signalling to drive drug resistance
27th February 2018
Researchers at the Barts Cancer Institute (BCI), Queen Mary University of London, led by Dr Richard Grose, Centre for Tumour Biology, have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells.
Read more
The involvement of the microenvironment in tumour evolution
15th February 2018
For the first time, researchers at the Barts Cancer Institute (BCI), Queen Mary University of London, have profiled what happens at the site of tumour metastasis as cancer grows and develops. By looking closely at the tumour microenvironment (TME), the team led by Professor Fran Balkwill, Lead for the Centre for Cancer & Inflammation, has identified changes that occur as a type of ovarian cancer evolves.
Read more
Steps towards the development of a new immunotherapy for pancreatic cancer
23rd January 2018
A research team led by Professor Yaohe Wang at the Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL) has created a novel oncolytic viral agent expressing interleukin-12 (IL-12) that shows promise as a potential anti-tumour immunotherapy for the treatment of pancreatic cancer.
Read more
Cost-effective testing for breast and ovarian cancer gene mutations
18th January 2018
Screening the entire population for breast and ovarian cancer gene mutations, as opposed to just those at high-risk of carrying this mutation, is cost effective and could prevent more ovarian and breast cancers than the current approach, according to research led by Barts Cancer Institute of Queen Mary University of London. The researchers believe that implementing a programme to test all British women over 30 years of age could result in thousands of fewer cases of ovarian and breast cancer; up to 17,000 fewer ovarian cancers and 64,000 fewer breast cancers over a lifetime.
Read more
Some leukaemia patients may be missing out on new treatments
11th January 2018
Patients with an aggressive form of leukaemia, currently ineligible for any type of targeted therapy, may in fact benefit from new drugs, according to new research by Barts Cancer Institute at Queen Mary University of London.
Read more